Arix Bioscience Placing - Now CLOSED

Subscribe for future offers from Cornhill Capital

This offer is now closed however, you can subscribe to hear about future IPO’s and placings direct from Cornhill Capital. No obligation to trade.

By submitting your personal information, you agree that Cornhill Capital may contact you regarding relevant content, products and special offers. You also agree that your personal information may be processed in the United Kingdom, and that you have read and agree to our Privacy Policy.

The Arix Bioscience Placing

17th August 2018

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, TO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (OTHER THAN THE UNITED KINGDOM) OR TO ANY NATIONAL, RESIDENT OR CITIZEN OF THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (OTHER THAN THE UNITED KINGDOM)

Arix Bioscience Placing - Offer Overview

  • Market Cap: £203.84m
  • Standard list
  • EPIC Code: ARIX.L
  • Intermediaries Offer
  • Raising up to: £100m
  • Fixed price offer: 225p
  • Healthcare sector

Expected Timetable

  • Offer Open

    28th February 2018

  • Books Close:

    15th March 2018 at 3pm

  • Allocation announced:

    16th March 2018

  • Trading begins:

    20th March 2018


About Arix Bioscience Plc

The growing number of innovations and developments in technology and therapies with in the healthcare sector has given rise to Arix Biosciences Plc. Arix globally source, finance and develop both start up and later stage companies in the healthcare and life sciences industry. The company provide support through their specialised clinical and commercialised strategy and extensive experience in academic science, to ensure each business can reach its full potential. 

Use of Proceeds:

  • Acquiring interests in new group businesses
  • Providing funding to support the expansion of its existing and new group businesses in excess of current contingent commitments.

News and Links:

https://arixbioscience.com/

LSE News

Business wire

Highlights
  • Arix Bioscience is a global healthcare and life science company focused on generating value from the development and commercialisation of innovative technologies and discoveries
  • Arix Bioscience’s Group Businesses are developing potentially breakthrough treatments in areas of significant unmet need
  • Balanced group with 13 direct interests spanning therapeutic areas, early to late stage development and geographies, plus indirect interests through fund management business and BioMotiv
  • Targeting a total of 20 direct holdings by end of 2018
  • Proven team of company builders with privileged relationships
  • Multiple milestones over next 18 months: currently 8 expected clinical data readouts
  • Four blue-chip pharma partnerships; Ipsen and Fosun added alongside UCB and Takeda

Risks*
  • Loss of key personnel could have a material adverse effect on the group
  • Failure or delay in completing clinical studies for any group businesses products may prevent it from obtaining regulatory approval which could incur additional costs and would delay and prevent receipt of any product revenue and delay commercialisation.
  • The intellectual property licenses of group businesses may become invalid, obsolete or uneconomical
  • The group may require additional financing in the long term, and there is no guarantee that it will be able to obtain such funding on commercially acceptable terms or at all
  • The Company may face competition, including from organisations with access to greater capital within the industry sector
  • Changes in legislation and policy may impact the resources and technology available to the Group
  • A Standard Listing affords less regulatory protection than a Premium Listing, which may have an adverse effect on the valuation of the Ordinary Shares
  • The groups success is dependent on its ability to identify develop and take to market viable products. The company cannot be certain that such a successful outcome is possible and they may fail to partner with or identify the most promising technologies in the industry
  • Arix is subject to risks associated with developments in the healthcare and life science sector. These can be characterised by rapid technological changes, frequent new product introductions, evolving industry standards and unforeseen costs

*Please note that these risks represent the judgement of Cornhill Capital, there may be additional risks represented in the prospectus


Offer Documents

Important information

Our service at a glance

Ready to invest?

To apply for shares, please follow this link below.


Need more help?

Please complete if you require further information or help from a member of staff who will talk you through the process, alternatively please call the new issues team on 020 3700 2500 :

We value your privacy and would never spam you

Cornhill Capital Limited is authorised and regulated by the Financial Conduct Authority (FRN 449720) and a member of the London Stock Exchange, Nex Exchange & Nasdaq Copenhagen.
Registered in England and Wales under registered number 5267797. Registered Office: 4th Floor, 18 St Swithins Lane, London, EC4N 8AD.


See What Our Clients Have to Say

I have been dealing with Cornhill for two years now and I’m very happy with the service. I’m confident that my account manager has my interests at heart and I appreciate the personal attention provided. I also get access to new issues, placings and market information usually only available to institutional investors. I would recommend Cornhill to active investors.

Mr. James Private Investor

Cornhill provide an excellent service for clients wishing to invest in IPOs and placings which are not generally available through the large retail client stock brokers. The terms and discounts available are generally the same as those offered to institutional investors, furthermore the AIM quoted investment opportunities often qualify or EIS tax reliefs.

Mr. Tim Private Investor

Risk Warning pre-IPO’s, IPO’s & Secondary Issues

Investments in pre-IPO’s and IPO’s involve a high degree of risk and are not suitable for all investors. A pre-IPO issue is the funding given to the company before listing. There is no guarantee that the company will list, but if it does then there is normally an increase from the pre-IPO to the IPO price, representing a profit. However, even when a company is listed on, say,  the AIM market, it is considered to be a high-risk investment, and will have wider spreads on price and be more illiquid and it may be difficult to sell the shares on a short-term basis and in some circumstances it may be difficult to sell at any price. All investments made into an IPO or new issue or in a secondary issue should always be made solely on the basis of the information provided in the relevant prospectus and any other supplementary documentation. The specific risks will be detailed in the prospectus but the value of your investment can go down as well as up and you may not get back the money you invested.  You should be sure that you fully understand the purpose of, and the reason for, the fundraising. Before you decide to invest you should obtain information regarding the business plan and note the risk factors. If you have any doubts about the suitability of an investment you should seek professional advice.

This announcement has been published by Cornhill Capital Limited.

This announcement has been prepared and is the sole responsibility of Cornhill Capital Limited of 4th Floor, 18 St Swithins Lane, London, EC4N 8AD, which is an authorised person for the purposes of the Financial Services and Markets Act 2000.

This announcement is not an offer of securities for sale in the United States. The securities to which this announcement relates have not been registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not he offered or sold in the United States absent registration or an exemption from registration under the Securities Act. There will be no public offering of the securities in the United States.